Curated News
By: NewsRamp Editorial Staff
July 07, 2026

VolitionRx's Nu.Q Assay Shows Prognostic Value in Lung Cancer Study

Discuss on LinkedIn Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • VolitionRx's Nu.Q Cancer Assay predicts lung cancer prognosis, enabling personalized treatment and improved outcomes, offering a competitive edge.
  • The Nu.Q Cancer Assay measures H3K27Me3-nucleosome levels, which are associated with cancer stage and survival, stratifying patients into risk groups.
  • This blood test could personalize lung cancer treatment, improving survival and quality of life for patients through earlier, more precise care.
  • A simple blood test using epigenetic biomarkers can predict lung cancer prognosis, potentially guiding treatment decisions more accurately.

Impact - Why it Matters

This study matters because it could revolutionize how lung cancer patients are managed. By using a simple blood test to accurately stratify risk, doctors can personalize treatment plans, potentially improving survival rates and reducing unnecessary side effects. For patients, this means more targeted, effective care from the moment of diagnosis. For healthcare systems, it offers a cost-effective tool to optimize resources and improve outcomes. VolitionRx's progress toward reimbursement in France also signals a step toward broader clinical adoption, making this technology accessible to more patients worldwide.

Summary

VolitionRx Limited (NYSE American: VNRX) has announced a landmark clinical study showcasing the prognostic power of its Nu.Q Cancer Assay in patients newly diagnosed with lung cancer. Conducted in collaboration with researchers and clinicians at France’s Hospices Civils de Lyon, this real-world study revealed that levels of the H3K27Me3-nucleosome biomarker are significantly associated with cancer stage, overall survival, and progression-free survival. A prognostic model that integrates this biomarker with clinical factors successfully stratified patients into low- and high-risk mortality groups, offering a new tool for personalized treatment decisions. The paper is currently under peer review, but the results are already generating excitement in the oncology community.

VolitionRx is now pursuing commercialization of the Nu.Q Cancer test, with clinical certification completed at Hospices Civils de Lyon and a reimbursement submission underway in France under the RIHN framework. The company is also exploring partnerships with hospital networks and international licensing opportunities. Reimbursement is seen as a critical milestone for routine clinical adoption in France, where the test could help clinicians tailor therapies and improve patient outcomes. This development underscores Volition’s commitment to advancing epigenetic diagnostics for early detection and monitoring of life-altering diseases, including cancer and sepsis.

VolitionRx is a multinational company focused on epigenetics, developing simple, cost-effective blood tests to detect and monitor diseases. Their research and development activities are based in Belgium, with offices in the U.S. and London. The company’s mission is to save lives and improve quality of life through earlier detection and treatment monitoring. For more details, the full press release is available at https://ibn.fm/dhJZ6.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, VolitionRx's Nu.Q Assay Shows Prognostic Value in Lung Cancer Study

blockchain registration record for this content.